motesanib was originally investigated for effectiveness against advanced nonsquamous non-small-cell lung cancer (nsclc), with phase ii trials indicating an effectiveness comparable to bevacizumab when they were both used in combination with paclitaxel/carboplatin. however a later and more detailed phase iii trial failed to show any benefit for the treatment of nsclc. a second phase iii trial was started in 2012, which focused on patients from asian backgrounds (performed on the bases of subgroup analysis) however this also failed to meet its primary endpoint.